e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Idiopathic pulmonary fibrosis and rarities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion
K. Oishi, K. Aoe, Y. Murata, K. Sakamoto, T. Ohfuji, W. Kotoku, Y. Ogata, T. Matsumoto, H. Ueoka, Y. Mimura (Ube, Japan)
Source:
Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Session:
Idiopathic pulmonary fibrosis and rarities
Session type:
Poster Discussion
Number:
462
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Oishi, K. Aoe, Y. Murata, K. Sakamoto, T. Ohfuji, W. Kotoku, Y. Ogata, T. Matsumoto, H. Ueoka, Y. Mimura (Ube, Japan). Prognostic factors analysis of patients with acute exacerbation of idiopathic interstitial pneumonias treated by polymyxin B hemoperfusion. Eur Respir J 2013; 42: Suppl. 57, 462
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Source: Eur Respir Rev 2009; 18: 129-132
Year: 2009
Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Acute exacerbation of idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 792
Year: 2004
Survival from acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with polymyxin B-immobilized fiber column: A retrospective analysis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience
Source: International Congress 2014 – ILDs 2
Year: 2014
Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Prognostic factors analysis of patients with rapid progressive interstitial pneumonias treated by direct hemoperfusion with polymyxin B-immobilized fiber column
Source: International Congress 2014 – ILDs 1
Year: 2014
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Survival after respiratory hospitalization in patients with idiopathic chronic fibrosing interstitial pneumonia
Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Year: 2018
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2014 – IPF and surroundings
Year: 2014
The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias
Source: Eur Respir Rev 2008; 17: 108-115
Year: 2008
Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016
Year: 2017
Exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2016 – Russia Session
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept